SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

URL

https://www.cell.com/cell/fulltext/S0092-8674(20)30229-4

Authors

Markus Hoffmann, Hanna Kleine-Weber, Simon Schroeder, Nadine Krüger, Tanja Herrler, Sandra Erichsen, Tobias S. Schiergens, Georg Herrler, Nai-Huei Wu, Andreas Nitsche, Marcel A. Müller, Christian Drosten, and Stefan Pöhlmann

Published Date

March 5, 2020

Publication

Cell

Organization

Leibniz Institute for Primate Research (Germany)

Medium

document

Topics

COVID-19,medical treatments,pharmaceuticals